Regina J. Lee

Regina J. Lee

Auto-generated profile, based on publicly available information

Regina J. Lee

Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2015 in Nature
Verified
Journal Article
Open access
PDF file
YKYanyong Kang
Yanyong Kang
XZX. Edward Zhou
X. Edward Zhou
XGXiang Gao
Xiang Gao
YHYuanzheng He
Yuanzheng He
WLWei Liu
Wei Liu
HXH. Eric Xu
H. Eric Xu
G-protein-coupled receptors (GPCRs) signal primarily through G proteins or arrestins. Arrestin binding to GPCRs blocks G protein interaction and redirects signalling to numerous G-protein-independent pathways. Here we report the crystal structure of a constitutively active form of human rhodopsin bound to a pre-activated form of the mouse visual arrestin, determined by serial femtosecond X-ray laser crystallography. Together with extensive biochemical and mutagenesis data, the structure reveals an overall architecture of the rhodopsin–arrestin assembly in which rhodopsin uses distinct structural elements, including transmembrane helix 7 and helix 8, to recruit arrestin. Correspondingly, arrestin adopts the pre-activated conformation, with a ∼20° rotation between the amino and carboxy domains, which opens up a cleft in arrestin to accommodate a short helix formed by the second intracellular loop of rhodopsin. This structure provides a basis for understanding GPCR-mediated arrestin-biased signalling and demonstrates the power of X-ray lasers for advancing the frontiers of structural biology.

1 February 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
LZLu Zhu
Lu Zhu
JAJoana Almaça
Joana Almaça
PDPrasanna K. Dadi
Prasanna K. Dadi
HHHao Hong
Hao Hong
WSWataru Sakamoto
Wataru Sakamoto
JWJurgen Wess
Jurgen Wess
β-arrestins are critical signalling molecules that regulate many fundamental physiological functions including the maintenance of euglycemia and peripheral insulin sensitivity. Here we show that inactivation of the β-arrestin-2 gene, barr2, in β-cells of adult mice greatly impairs insulin release and glucose tolerance in mice fed with a calorie-rich diet. Both glucose and KCl-induced insulin secretion and calcium responses were profoundly reduced in β-arrestin-2 (barr2) deficient β-cells. In human β-cells, barr2 knockdown abolished glucose-induced insulin secretion. We also show that the presence of barr2 is essential for proper CAMKII function in β-cells. Importantly, overexpression of barr2 in β-cells greatly ameliorates the metabolic deficits displayed by mice consuming a high-fat diet. Thus, our data identify barr2 as an important regulator of β-cell function, which may serve as a new target to improve β-cell function.

26 June 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LZLu Zhu
Lu Zhu
MRMario Rossi
Mario Rossi
YCYinghong Cui
Yinghong Cui
RLRegina J. Lee
Regina J. Lee
WSWataru Sakamoto
Wataru Sakamoto
JWJurgen Wess
Jurgen Wess
An increase in hepatic glucose production (HGP) represents a key feature of type 2 diabetes. This deficiency in metabolic control of glucose production critically depends on enhanced signaling through hepatic glucagon receptors (GCGRs). Here, we have demonstrated that selective inactivation of the GPCR-associated protein β-arrestin 2 in hepatocytes of adult mice results in greatly increased hepatic GCGR signaling, leading to striking deficits in glucose homeostasis. However, hepatocyte-specific β-arrestin 2 deficiency did not affect hepatic insulin sensitivity or β-adrenergic signaling. Adult mice lacking β-arrestin 1 selectively in hepatocytes did not show any changes in glucose homeostasis. Importantly, hepatocyte-specific overexpression of β-arrestin 2 greatly reduced hepatic GCGR signaling and protected mice against the metabolic deficits caused by the consumption of a high-fat diet. Our data support the concept that strategies aimed at enhancing hepatic β-arrestin 2 activity could prove useful for suppressing HGP for therapeutic purposes.

16 January 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MRMario Rossi
Mario Rossi
LZLu Zhu
Lu Zhu
SMSara M. McMillin
Sara M. McMillin
SPSai Prasad Pydi
Sai Prasad Pydi
SJShanu Jain
Shanu Jain
JWJurgen Wess
Jurgen Wess
An increase in hepatic glucose production (HGP) is a key feature of type 2 diabetes. Excessive signaling through hepatic Gs–linked glucagon receptors critically contributes to pathologically elevated HGP. Here, we tested the hypothesis that this metabolic impairment can be counteracted by enhancing hepatic Gi signaling. Specifically, we used a chemogenetic approach to selectively activate Gi-type G proteins in mouse hepatocytes in vivo. Unexpectedly, activation of hepatic Gi signaling triggered a pronounced increase in HGP and severely impaired glucose homeostasis. Moreover, increased Gi signaling stimulated glucose release in human hepatocytes. A lack of functional Gi-type G proteins in hepatocytes reduced blood glucose levels and protected mice against the metabolic deficits caused by the consumption of a high-fat diet. Additionally, we delineated a signaling cascade that links hepatic Gi signaling to ROS production, JNK activation, and a subsequent increase in HGP. Taken together, our data support the concept that drugs able to block hepatic Gi–coupled GPCRs may prove beneficial as antidiabetic drugs.

1 April 2019 in Diabetes
Verified
Journal Article
Open access
PDF file
DBDerek B.J. Bone
Derek B.J. Bone
JMJaroslawna Meister
Jaroslawna Meister
JKJonas R. Knudsen
Jonas R. Knudsen
DDDiptadip Dattaroy
Diptadip Dattaroy
ACAmanda Cohen
Amanda Cohen
JWJurgen Wess
Jurgen Wess
Skeletal muscle (SKM) insulin resistance plays a central role in the pathogenesis of type 2 diabetes. Because G-protein–coupled receptors (GPCRs) represent excellent drug targets, we hypothesized that activation of specific functional classes of SKM GPCRs might lead to improved glucose homeostasis in type 2 diabetes. At present, little is known about the in vivo metabolic roles of the various distinct GPCR signaling pathways operative in SKM. In this study, we tested the hypothesis that selective activation of SKM Gq signaling can improve SKM glucose uptake and whole-body glucose homeostasis under physiological and pathophysiological conditions. Studies with transgenic mice expressing a Gq-linked designer GPCR selectively in SKM cells demonstrated that receptor-mediated activation of SKM Gq signaling greatly promoted glucose uptake into SKM and significantly improved glucose homeostasis in obese, glucose-intolerant mice. These beneficial metabolic effects required the activity of SKM AMPK. In contrast, obese mutant mice that lacked both Gαq and Gα11 selectively in SKM showed severe deficits in glucose homeostasis. Moreover, GPCR-mediated activation of Gq signaling also stimulated glucose uptake in primary human SKM cells. Taken together, these findings strongly suggest that agents capable of enhancing SKM Gq signaling may prove useful as novel antidiabetic drugs.

17 October 2019 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
JMJaroslawna Meister
Jaroslawna Meister
DBDerek B J Bone
Derek B J Bone
GGGrzegorz Godlewski
Grzegorz Godlewski
ZLZiyi Liu
Ziyi Liu
RLRegina J Lee
Regina J Lee
JWJurgen Wess
Jurgen Wess
Type 2 diabetes (T2D) has become a major health problem worldwide. Skeletal muscle (SKM) is the key tissue for whole-body glucose disposal and utilization. New drugs aimed at improving insulin sensitivity of SKM would greatly expand available therapeutic options. β-arrestin-1 and -2 (Barr1 and Barr2, respectively) are two intracellular proteins best known for their ability to mediate the desensitization and internalization of G protein-coupled receptors (GPCRs). Recent studies suggest that Barr1 and Barr2 regulate several important metabolic functions including insulin release and hepatic glucose production. Since SKM expresses many GPCRs, including the metabolically important β2-adrenergic receptor, the goal of this study was to examine the potential roles of Barr1 and Barr2 in regulating SKM and whole-body glucose metabolism. Using SKM-specific knockout (KO) mouse lines, we showed that the loss of SKM Barr2, but not of SKM Barr1, resulted in mild improvements in glucose tolerance in diet-induced obese mice. SKM-specific Barr1- and Barr2-KO mice did not show any significant differences in exercise performance. However, lack of SKM Barr2 led to increased glycogen breakdown following a treadmill exercise challenge. Interestingly, mice that lacked both Barr1 and Barr2 in SKM showed no significant metabolic phenotypes. Thus, somewhat surprisingly, our data indicate that SKM β-arrestins play only rather subtle roles (SKM Barr2) in regulating whole-body glucose homeostasis and SKM insulin sensitivity. Type 2 diabetes (T2D) has become a major health problem worldwide. The key feature of T2D is that blood glucose levels are elevated above the normal range. When blood glucose levels rise, insulin is released from the pancreas, triggering the rapid removal of glucose from the blood. Because of the large mass of skeletal muscle tissue (SKM), insulin-stimulated glucose uptake into SKM is essential for maintaining normal blood glucose levels. In T2D, insulin-stimulated glucose uptake by SKM is significantly impaired. Recent research has shown that two intracellular proteins known as β-arrestin-1 and -2 (Barr1 and Barr2, respectively) play important roles in regulating blood glucose levels. In this study, we investigated the potential roles of SKM Barr1/2 in maintaining normal blood glucose levels. We generated and analyzed several mutant mice that lacked either Barr1 or Barr2 or both Barr1 and Barr2 selectively in SKM. Surprisingly, we found that SKM β-arrestins play only rather subtle roles (SKM Barr2) in regulating blood glucose levels and the responsiveness of SKM to insulin. These findings are important for developing novel anti-diabetic drugs that act by promoting glucose uptake into SKM.